A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide VAC Alternating with Vincristine and Irinotecan VI versus VAC/VI plus Temsirolimus TORI, Torisel, NSC 683864 in Patients with Intermediate Risk IR Rhabdomyosarcoma RMS

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT02567435

Study #:
CMH - ARST1431

Start Date:
Jul 16, 2018

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02567435

View Complete Trial Details & Eligibility at ClinicalTrials.gov